Jiangsu Nhwa Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 1999-03-29
- Employees
- 5.3K
- Market Cap
- -
- Website
- http://www.nhwa-group.com
Clinical Trials
7
Active:0
Completed:3
Trial Phases
4 Phases
Phase 1:3
Phase 2:1
Phase 4:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (42.9%)Phase 4
2 (28.6%)Not Applicable
1 (14.3%)Phase 2
1 (14.3%)A Study of NH280105 in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- Alzheimer Disease
- Interventions
- Drug: NH280105- SADDrug: NH280105- MADDrug: Placebo
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06870058
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
A Phase II Study to Evaluate NH102 for Depression
Phase 2
Recruiting
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06842992
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Single Ascending Dose Study of NH102 in Healthy Subjects
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT05015192
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects
Phase 1
- Conditions
- Schizophrenia
- Interventions
- Drug: 18mg CY150112Drug: 24mg CY150112Drug: 0.5mg CY150112Drug: 1.5mg CY150112Drug: 4.5mg CY150112Drug: 10mg CY150112
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04839926
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients
Phase 4
Completed
- Conditions
- Efficacy and Safety of Mivacurium Chloride for Pediatric Patients
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1152
- Registration Number
- NCT02117401
- Prev
- 1
- 2
- Next
News
No news found